Investing

Allogene Therapeutics : ALLO

ALLO

Stock Data

$2.15

$0.02 (0.94%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Allogene Therapeutics Inc is at the forefront of developing innovative cancer treatments. Focused on immuno-oncology, this company is working on creating genetically engineered allogeneic T cell therapies. Its pipeline includes promising candidates like UCART19 for B-cell ALL and ALLO-501 for non-Hodgkin lymphoma, among others targeting various cancers. With strategic collaborations, including with Pfizer and The University of Texas MD Anderson Cancer Center, Allogene aims to revolutionize cancer treatment. Founded in 2017, its headquarters are in South San Francisco, California.

All Allogene Therapeutics Articles

9 Articles

Joshua Rodriguez | Sep 7, 2024 at 7:55 AM EDT

3 Hot Penny Stocks to Buy With $1000

Penny stocks are some of my favorite stocks to watch. When these young budding companies release news, their stock prices…

Trey Thoelcke | May 26, 2024 at 9:15 AM EDT

Insider Buying of These 6 Stocks Surges: Fracking, Boats, a Buyout Candidate

With the earnings season winding down and windows for making insider purchases opening up, insiders have been scooping up shares…

Lee Jackson | Mar 4, 2023 at 6:05 AM EST

Goldman Sachs Has 5 Stellar Stocks to Buy Under $10 With Up to 735% Upside Potential

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential.…

Chris Lange | Dec 12, 2022 at 9:00 AM EST

Monday’s Top Analyst Upgrades and Downgrades: Analog Devices, Baxter, Best Buy, Coinbase, Johnson Controls, Lam Research, Micron Technology, Qualcomm and More

Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research,…

Lee Jackson | Dec 1, 2022 at 8:47 AM EST

Thursday’s Top Analyst Upgrades and Downgrades: Carvana, CrowdStrike, Foot Locker, Rivian, Shopify, UnitedHealth and More

Thursday's top analyst upgrades and downgrades included AppLovin, Carvana, CrowdStrike, DocuSign, Fisker, Foot Locker, Intuitive Surgical, Rivian Automotive, Shopify, UnitedHealth,…

Chris Lange | Jul 15, 2022 at 11:05 AM EDT

More Problems More Spending: Analysts Upgrade or Downgrade CSX, Qualcomm and More

Friday's additional top analyst upgrades and downgrades included Allogene Therapeutics, CSX, Norfolk Southern, Qualcomm, Toyota and Yelp.

Chris Lange | Dec 15, 2021 at 7:40 AM EST

Cathie Wood’s ARK Invest Buys Over 1.5 Million Shares of Allogene

One of Cathie Wood's ARK Invest exchange-traded funds bought over 1.5 million shares of Allogene on December 14.

Lee Jackson | Oct 8, 2021 at 9:00 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: Caesars, Charter, Corning, GE, Home Depot, Plug Power, 3M and More

Friday's top analyst upgrades and downgrades included Caesars Entertainment, Charter Communications, Conagra Brands, Corning, Denny’s, General Electric, Home Depot, Plug…

Chris Lange | Jun 21, 2021 at 9:08 AM EDT

Monday’s Top Analyst Upgrades and Downgrades: Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and More

Monday’s top analyst upgrades and downgrades included Accenture, Arcturus, Elastic, Marathon, Riot Blockchain, ResMed, Sykes Enterprises, Western Alliance Bancorp and…